Selected stock price target news of the day - March 18th, 2025

By: Matthew Otto

Belite Bio Reports Q4 and Full-Year 2024 Results, Updates on Phase 3 Trials and $15 Million Fundraising

Belite Bio announced that the Data Safety Monitoring Board (DSMB) recommended the continuation of the Phase 3 DRAGON trial in adolescent Stargardt disease (STGD1) without modifications, with trial completion expected in Q4 2025.

The trial, which has enrolled 104 subjects, aims to provide treatment options for approximately 150,000 individuals worldwide affected by STGD1. Enrollment in the Phase 3 PHOENIX trial for geographic atrophy (GA) has reached 406 subjects out of a planned 500. Targeting a patient population of nearly 5 million people globally who suffer from GA, the advanced form of dry age-related macular degeneration (AMD). Additionally, Belite Bio completed a $15 million registered direct offering on February 5, 2025. With the potential for an additional $15 million from warrant exercises.

Financially, Belite Bio ended 2024 with $31.7 million in cash and $113.5 million in liquidity funds, time deposits, and U.S. Treasury bills. Research and development expenses increased to $7.3 million in Q4 2024 from $4.9 million in Q4 2023, while full-year R&D expenses rose to $29.9 million from $24.8 million. General and administrative expenses grew to $4.2 million for Q4 2024 and $10.1 million for the full year, compared to $2.1 million and $6.8 million, respectively, in 2023.

Other income was $1.4 million for the quarter and $3.9 million for the full year, primarily from interest on investments. Belite Bio reported a net loss of $10.1 million ($0.32 per share) in Q4 2024, compared to $7.0 million ($0.25 per share) in Q4 2023. For the full year, the net loss was $36.1 million ($1.18 per share) versus $31.6 million ($1.19 per share) in 2023. Belite Bio’s Q4 earnings per share (EPS) of ($0.32) aligned with analyst estimates.

Analysts Reaffirm Ratings Amid Clinical and Financial Updates

Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating.
HC Wainwright & Co. analyst Yi Chen reaffirmed a Buy rating and a $100 price target.

Which Analyst has the best track record to show on BLTE?

Analyst Yi Chen (HC WAINWRIGHT) currently has the highest performing score on BLTE with 14/15 (93.33%) price target fulfillment ratio. His price targets carry an average of $17.77 (21.61%) potential upside. Belite Bio stock price reaches these price targets on average within 355 days.

SAIC Exceeds Q4 Earnings and Revenue Estimates, Introduces FY26 Guidance Above Consensus

Science Applications International Corporation (SAIC) reported fourth-quarter fiscal 2025 revenues of $1.84 billion, exceeding the consensus estimate of $1.81 billion and reflecting 5.8% organic growth. Full-year revenues reached $7.48 billion, with 3.1% organic growth. Quarterly earnings per share of $2.57 surpassed analyst expectations by $0.49, while full-year earnings per share rose 16% to $9.13.

SAIC generated $115 million in operating cash flow for the quarter and $494 million for the full year, with free cash flow totaling $236 million in the quarter and $499 million for the year. Net bookings for the quarter were $1.3 billion, resulting in a book-to-bill ratio of 0.7, while the full-year book-to-bill ratio stood at 0.9.

Operating income for the quarter increased 75% to $138 million, with a margin improvement of 300 basis points to 7.5%. Full-year operating income was $563 million, reflecting a 24% decline due to a prior-year gain from the divestiture of the Supply Chain Business. Cash deployment for the year included $527 million in share repurchases, $75 million in dividends, and $36 million in capital expenditures.

SAIC ended the year with an estimated $21.9 billion backlog, of which $3.4 billion was funded. SAIC introduced fiscal 2026 guidance above prior targets, projecting earnings per share between $9.10 and $9.30, surpassing the consensus estimate of $8.85. Revenue guidance for fiscal 2026 is set between $7.60 billion and $7.75 billion, exceeding the consensus estimate of $7.63 billion.

Analyst Price Targets Raised Following Q4 Results

UBS analyst Gavin Parsons maintained a Neutral rating while raising the price target from $123 to $126.
Wells Fargo analyst Matthew Akers kept an Overweight rating and lifted the price target from $139 to $148.

Which Analyst has the best track record to show on SAIC?

Analyst Gavin Parsons (UBS) currently has the highest performing score on SAIC with 10/11 (90.91%) price target fulfillment ratio. His price targets carry an average of $-10.15 (-8.97%) potential downside. Science Applications International Corporation stock price reaches these price targets on average within 219 days.

Meta Expands Fact-Checking Efforts in Australia Ahead of Election

Meta Platforms announced on Tuesday that its independent fact-checking program in Australia will work to detect and reduce the spread of false content and deepfakes ahead of the national election due by May.

Meta’s Head of Policy in Australia, Cheryl Seeto, noted that warning labels would be attached to debunked content, reducing its visibility by up to 95% in feeds. The initiative involves collaboration with news agencies Agence France-Presse and the Australian Associated Press. Meta’s fact-checking program currently operates in over 60 countries and 40 languages. Beyond misinformation, Meta is also addressing AI-generated deepfakes, which have increased by over 900% in the past five years. Meta reported that any deepfake content violating its policies would either be removed or labeled as “altered” and ranked lower in feeds, reducing its visibility by more than 80%. Users will also receive prompts to disclose AI-generated content when sharing it.

The announcement comes as Meta faces regulatory challenges in Australia, including a proposed levy on big tech firms, estimated to generate over $130 million annually. Additionally, Meta and other social media companies must implement age restrictions, enforcing a ban on users under 16—affecting approximately 3.5 million Australians—by the end of the year. The Australian election remains closely contested, with opinion polls showing the opposition Liberal-National coalition holding a narrow lead of 51% to 49% over the ruling Labor party.

Analyst Lowers Target Amid Fact-Checking Expansion

Keybanc analyst Jason Celino maintained an Overweight rating and lowered the price target from $750 to $710.

Which Analyst has the best track record to show on META?

Analyst Thomas Champion (PIPER SANDLER) currently has the highest performing score on META with 24/26 (92.31%) price target fulfillment ratio. His price targets carry an average of $88 (12.81%) potential upside. Meta Platforms stock price reaches these price targets on average within 215 days.